ImmuCell Co. (NASDAQ:ICCC) saw a significant drop in short interest in the month of June. As of June 30th, there was short interest totalling 3,200 shares, a drop of 57.3% from the May 30th total of 7,500 shares. Based on an average daily volume of 7,500 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.1% of the company’s stock are short sold.
An institutional investor recently raised its position in ImmuCell stock. Ingalls & Snyder LLC lifted its holdings in shares of ImmuCell Co. (NASDAQ:ICCC) by 5.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 96,243 shares of the biotechnology company’s stock after purchasing an additional 4,732 shares during the quarter. Ingalls & Snyder LLC owned 1.33% of ImmuCell worth $626,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 22.62% of the company’s stock.
Shares of NASDAQ ICCC traded down $0.29 during mid-day trading on Friday, reaching $6.04. 20,512 shares of the company’s stock were exchanged, compared to its average volume of 5,965. The company has a debt-to-equity ratio of 0.27, a current ratio of 7.26 and a quick ratio of 6.25. The firm’s fifty day moving average is $6.49. ImmuCell has a twelve month low of $5.55 and a twelve month high of $9.30.
ImmuCell (NASDAQ:ICCC) last released its quarterly earnings results on Monday, May 13th. The biotechnology company reported $0.03 EPS for the quarter. The company had revenue of $4.41 million for the quarter. ImmuCell had a negative return on equity of 5.71% and a negative net margin of 15.62%.
ImmuCell Company Profile
ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E.
Featured Article: Average Daily Trade Volume Explained
Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.